Navigation Links
New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
Date:6/15/2009

Bill would remove financial penalties for participating in research studies

BETHESDA, Md., June 15 /PRNewswire-USNewswire/ -- New legislation introduced today would allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for government healthcare coverage.

The "Improve Access to Clinical Trials Act" is co-sponsored by Representatives Edward J. Markey (D-MA) and Cliff Stearns (R-FL) and 30 members of the House of Representatives.

Current law prevents many people who receive Supplemental Security Income (SSI) from accepting research compensation because it would make them ineligible to continue receiving government medical benefits. This financial penalty prevents significant numbers of people with rare diseases from participating in clinical studies.

Researchers developing drugs to treat rare diseases struggle to recruit participants for clinical trials because of limited patient populations. This is particularly true for cystic fibrosis (CF). More than 30 promising CF drugs are in development, yet only about 30,000 people in the U.S. have this life-threatening, genetic disease.

"We are grateful to Representatives Edward Markey and Cliff Stearns for introducing this important bill that allows more people with rare diseases - including cystic fibrosis - to participate in clinical trials," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "Cystic fibrosis is a devastating disease and this new legislation clears the way for promising drugs to move more swiftly from the research phase into the hands of people who need them."

Fifty years ago, there were no drugs for people with CF and those with the disease rarely lived to attend elementary school. Today, because of the Cystic Fibrosis Foundation's focus on innovative and aggressive research, there are more than 30 potential therapies in development, and the median life expectancy is higher than 37 years.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has more than 70 chapters and branch offices throughout the country, and supports and accredits a nationwide network of 110 CF care centers, which provide vital treatments and other CF resources to patients and families.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. California Legislature Passes Historic HIV Testing Bill (AB 682); AHF Urges Governor to Sign Crucial Lifesaving Legislation
2. Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis
3. Gates Foundation Seeks Proposals for Innovative Global Health Research
4. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
5. Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial
6. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
7. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
8. New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer
9. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
10. New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus
11. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Research and Markets has announced the ... Technologies" report to their offering. ... Traditional medical devices include ... non-drug coated implantables, large endoscopes, needle based drug delivery, lab ... last two to three decades for the treatment and management ...
(Date:2/16/2017)... 2017 DaVita Inc. (NYSE: DVA ) ... 31, 2016. Net income attributable to DaVita ... was $158 million, or $0.80 per share and $880 million, ... income attributable to DaVita Inc. for the quarter and year ... was $192 million, or $0.98 per share, and $789 million, ...
(Date:2/16/2017)... , Feb. 16, 2017  Aralez Pharmaceuticals Inc. ... specialty pharmaceutical company, today announced that executive management will ... to be held February 22-23, 2017. Adrian Adams ... the Company at 1:35 p.m. local time on Wednesday, ... audio archive for the event may be accessed from ...
Breaking Medicine Technology:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for ... so many other applications. Users can pick and choose from hand-crafted trend-setting ...
(Date:2/17/2017)... ... 17, 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, ... and non-controlled substances plus the ability to manage orders on their desktop or ... accept electronic prescriptions, according to the Office of the National Coordinator of Health ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... ... 17, 2017 , ... PrideStaff, a national staffing organization, is ... Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , Now in ... to the staffing industry over the last twelve months. Industry insiders and observers ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... planning assistance to families and business owners in the greater Fort Lauderdale metropolitan ... organization. , For more than 30 years, LifeNet 4 Families has provided ...
Breaking Medicine News(10 mins):